Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
04/2012
04/19/2012US20120095081 Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1
04/19/2012US20120095076 Compositions and methods for inhibiting expression of huntingtin gene
04/19/2012US20120095072 Crystalline Sodium Atorvastatin
04/19/2012US20120095071 3-(3-indolyl) propionic acid calcium salt and method of making 3-(3-indolyl) propionic acid free acid therefrom
04/19/2012US20120095065 Macrocyclic compounds and methods of treatment
04/19/2012US20120095063 Methods and compositions for treatment of ischemic conditions and conditions related to mitochondrial function
04/19/2012US20120095062 Tricyclic compounds, compositions, and methods
04/19/2012US20120095061 Fluorinated Derivatives of Deferiprone
04/19/2012US20120095056 2,5-disubstituted tetrazole derivatives and their use as nicotinic acetylcholine receptor modulators
04/19/2012US20120095055 HEXAHYDROCYCLOPENTYL[f]INDAZOLE 5-HYDROXYMETHYL ETHANOLS AND DERIVATIVES THEREOF AS SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS
04/19/2012US20120095049 Nociceptin analogs
04/19/2012US20120095048 Allosteric binding compounds
04/19/2012US20120095047 Novel Heteropyrrole Analogs Acting on Cannabinoid Receptors
04/19/2012US20120095046 Amido-Isothiazole Compounds and Their Use as Inhibitors of 11Beta-HSD1 for the Treatment of Metabolic Syndrome and Related Disorders
04/19/2012US20120095040 Cyclopenta[c]pyrrole-2-carboxylate derivatives, preparation thereof and therapeutic use thereof
04/19/2012US20120095039 Heterocyclic compounds with affinity to muscarinic receptors
04/19/2012US20120095036 Novel substituted indazole and aza-indazole derivatives as gamma secretase modulators
04/19/2012US20120095034 Piperidine derivatives useful as orexin receptor antagonists
04/19/2012US20120095033 Selective Glycosidase Inhibitors and Uses Thereof
04/19/2012US20120095031 Cyclopropane compound
04/19/2012US20120095028 3-oxa-7-azabicyclo[3.3.1]nonanes
04/19/2012US20120095025 SUBSTITUTED [1,2,4]TRIAZOLO[1,5-a]PYRIMIDINES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS
04/19/2012US20120095022 Derivatives of 10-amino-1,2,3,4-tetrahydropyrido[2,1-a]isoindol-6(10bh)-ones, method for preparation thereof and therapeutic uses thereof
04/19/2012US20120095018 5-ht1a receptor subtype agonist
04/19/2012US20120095016 Therapeutic 5,6,5-tricyclic analogs
04/19/2012US20120095015 Triazole compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor
04/19/2012US20120095010 Tricyclic delta-opioid modulators
04/19/2012US20120095007 Carbamoyloxy arylalkan arylpiperazine analgesics
04/19/2012US20120095005 Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors
04/19/2012US20120095003 Methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof
04/19/2012US20120095000 Compounds for activating tgf-beta signaling
04/19/2012US20120094996 Imidazo [2, 1-B] [1, 3, 4] Thiadiazole Derivatives
04/19/2012US20120094995 2-aza-bicyclo[2.2.1]heptane compounds and uses thereof
04/19/2012US20120094992 Poly (adp-ribose) polymerase (parp) inhibitors
04/19/2012US20120094991 1, 4-Benzoxazine Compounds and Derivatives Thereof as Therapeutic Drugs for the Treatment of Neurodegenerative Conditions
04/19/2012US20120094990 Phenylacetic acid compound
04/19/2012US20120094987 SUBSTITUTED PYRIDO [3', 2': 4, 5] THIENO [3, 2-D] PYRIMIDINES AND PYRIDO [3', 2': 4, 5] FURO [3, 2-D] PYRIMIDINES USED AS INHIBITORS OF THE PDE-4 AND/OR THE RELEASE OF TNF-alpha
04/19/2012US20120094985 Pharmaceutical compositions comprising chlorophenyl piperazine derived compounds and use of the compounds in producing medicaments
04/19/2012US20120094984 Fused aminodihydrothiazine derivatives
04/19/2012US20120094979 Thiazole or thiadizaloe derivatives for use as sphingosine 1-phosphate 1 (s1p1) receptor agonists
04/19/2012US20120094971 Compositions Including 6-Aminohexanoic Acid Derivatives As HDAC Inhibitors
04/19/2012US20120094970 NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE
04/19/2012US20120094966 Organic compounds
04/19/2012US20120094964 Sulfamoyl benzoic acid derivatives as trpm8 antagonists
04/19/2012US20120094957 Inhibitors of fatty acid amide hydrolase
04/19/2012US20120094950 Nutraceutical Composition and Methods for Preventing or Treating Multiple Sclerosis
04/19/2012US20120094943 Alpha 7 nicotinic receptor selective ligands
04/19/2012US20120094942 Chemosensory Receptor Ligand-Based Therapies
04/19/2012US20120094941 Mangiferin-Berberine Salt, Manufacturing Method and Use Thereof
04/19/2012US20120094934 Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
04/19/2012US20120094922 Screening assays for agents that alter inhibitor of apoptosis (iap) protein regulation of caspase activity
04/19/2012US20120094916 Altering memory by affecting staufen function
04/19/2012US20120094915 Anti-mental fatigue drug
04/19/2012US20120094911 Endokinin c/d-derived peptides
04/19/2012US20120094904 Fad4, fad5, fad5-2, and fad6, novel fatty acid desaturase family members and uses thereof
04/19/2012US20120094894 Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
04/19/2012US20120094293 PGC-1ß, A NOVEL PGC-1 HOMOLOGUE AND USES THEREFOR
04/19/2012US20120093948 Nitric Oxide Treatments
04/19/2012US20120093941 Neutrophil-depleted platelet rich plasma formulations for cardiac treatments
04/19/2012US20120093938 Orally disintegrating tablets comprising diphenhydramine
04/19/2012US20120093936 Method and device for treatment of conditions associated with inflammation or undesirable activation of the immune system
04/19/2012US20120093933 Denatured lactoglobulin and polyphenol coassemblies
04/19/2012US20120093930 Article and method for focused delivery of therapeutic and/or diagnostic materials
04/19/2012US20120093929 Opioid Composition for Treating Skin Lesions
04/19/2012US20120093923 Apparatus And Methods For Delivering A Plurality Of Medicaments For Management Of Co-Morbid Diseases, Illnesses, Or Conditions
04/19/2012US20120093922 Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
04/19/2012US20120093916 Devices, Systems and Methods for Improving Memory and/or Cognitive Function Through Brain Delivery of SIRNA
04/19/2012US20120093915 Vectors including an anionic macromolecule and a cationic lipid for delivering small nucleic acids
04/19/2012US20120093887 Amorphous varenicline tartrate co-precipitates
04/19/2012US20120093885 Therapeutic vesicles
04/19/2012US20120093883 Method of treating and preventing neuro-olfactory triggered or aggravated illnesses or related conditions
04/19/2012US20120093882 Stable pharmaceutical compositions of diclofenac
04/19/2012US20120093875 Aminocyclitol compounds, process for obtaining them and uses
04/19/2012US20120093833 Human Oncostatin M Antibodies and Methods of Use
04/19/2012US20120093832 Promotion of neuronal integration in neural stem cell grafts
04/19/2012US20120093829 New methods for treatment of inflammatory diseases
04/19/2012US20120093822 Dopamine d2 receptor-disc1 interaction, compositions and methods for modulating same
04/19/2012US20120093816 Use of TNF-alpha Inhibitors for Treating a Nerve Disorder Mediated by Nucleus Pulposus
04/19/2012US20120093812 Method of Treating Degenerative Disorders of the Nervous System
04/19/2012US20120093807 Ror alpha promoting the induction of bmall
04/19/2012US20120093798 Methods for Treatment of Stroke or Cerebrovascular
04/19/2012US20120093785 Human artificial chromosome (hac) vector
04/19/2012US20120093725 Fucoidans as Ligands for the Diagnosis of Degenerative Pathologies
04/19/2012US20120093722 Synthetic diblock copolypeptide hydrogels for use in the central nervous system
04/19/2012US20120093716 Use of antisecretory factors (af) for optimizing cellular uptake
04/19/2012US20120091605 Chewable Soft Capsule
04/19/2012US20120091022 Sustained-release formulation for injection
04/19/2012DE102010048883A1 Use of buprenorphine for abuse protection in pharmaceutical compositions containing a opioid full-agonist
04/19/2012CA2817973A1 Antibodies that bind amyloid oligomers
04/19/2012CA2814628A1 Acylbenzene derivative
04/19/2012CA2814540A1 Inhibitors of p75 receptor and their uses
04/19/2012CA2814442A1 Hypocholesterolemic, anti-inflammatory and antiepileptic neuroprotective compound
04/19/2012CA2813936A1 Novel pyridyl benzoxazine derivatives, pharmaceutical composition comprising the same, and use thereof
04/19/2012CA2813648A1 Combinations of serotonin receptor agonists for treatment of movement disorders
04/19/2012CA2812948A1 Nd2 peptides and methods of treating neurological disease
04/19/2012CA2811583A1 Method for producing and using a copolymer of sodium carboxymethyl cellulose and gossypol
04/19/2012CA2809966A1 Treatment for cocaine addiction
04/18/2012EP2441847A2 Screening methods using syk in combination with tau protein
04/18/2012EP2441774A1 Peptides having zinc finger domains and uses thereof
04/18/2012EP2441766A1 Nalmefene hydrochloride dihydrate
1 ... 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 ... 1833